Waldenstrom's Macroglobulinemia
40
0
2
29
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
24 trials with published results (60%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
20.0%
8 terminated out of 40 trials
78.4%
-8.1% vs benchmark
0%
0 trials in Phase 3/4
83%
24 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (40)
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Study of MLN8237 in Participants With Advanced Hematological Malignancies
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia